What is Semaglutide?
Semaglutide is a synthetic peptide analog of naturally occurring glucagon-like peptide-1 (GLP-1), belonging to the class of incretin mimetics. This compound was developed by Novo Nordisk and is structurally based on human GLP-1, with specific amino acid modifications that enhance its pharmacological properties. The molecule consists of 31 amino acids and contains a fatty acid chain covalently bound to lysine at position 26, which ensures an extended half-life through binding to albumin. These structural adjustments make semaglutide particularly suitable for research into glucose regulation and metabolic processes.
Mechanism of Action
Semaglutide acts as a selective agonist of the GLP-1 receptor (GLP-1R), a G-protein coupled receptor primarily expressed in pancreatic islets, gastrointestinal tract, kidneys, and brain. Upon binding to the GLP-1R, semaglutide activates the adenylyl cyclase pathway, resulting in increased intracellular cAMP concentrations. This leads to glucose-dependent insulin secretion in pancreatic β-cells and inhibition of glucagon secretion in α-cells. Additionally, semaglutide delays gastric emptying by interacting with receptors in the hypothalamus and the autonomic nervous system. The peptide also modulates food intake by activating satiety signals via the arcuate nucleus in the hypothalamus, which has important implications for metabolic research.
Research Results
In preclinical studies, semaglutide has demonstrated consistent effects on glucose homeostasis. Research in diabetic mouse models showed a significant reduction in fasting glucose (average 35-45% reduction) and improved glucose tolerance within 4 weeks of treatment. Studies in Zucker diabetic rats demonstrated that semaglutide preserved β-cell mass and reduced apoptosis by 60% compared to control groups. In vitro research on isolated pancreatic islets showed glucose-stimulated insulin secretion (GSIS) increases of 2.5-4 times baseline values at physiological glucose concentrations. Cell culture studies have shown that semaglutide has neuroprotective effects in neuronal cell lines, with a 40-50% reduction in oxidative stress markers. Research into cardiovascular effects in ex vivo heart models showed improved endothelial function and reduced inflammatory markers.
Available Variants and Purity
Dutch Peptide Labs offers semaglutide in four research variants: 5mg (€40), 10mg (€59), 20mg (€85), and 30mg (€109). All our semaglutide batches are produced according to pharmaceutical standards and undergo rigorous quality control. The peptide is delivered with a guaranteed purity of ≥99.9%, verified by HPLC-MS analysis. Each batch is independently tested by accredited laboratories for identity, purity, and microbial contamination. Provided Certificates of Analysis (COA) contain detailed specifications and test results for full traceability in your research.
Storage and Handling
Semaglutide should be stored at -20°C in its original packaging, protected from light and moisture. With correct storage, the peptide remains stable for at least 24 months. For reconstitution, sterile water or bacteriostatic water is recommended, and the solution should be mixed gently to prevent aggregation. Reconstituted solutions are stable for 72 hours at 2-8°C. For long-term storage of solutions, adding 10% glycerol and storing at -20°C is recommended. Avoid repeated freezing and thawing. Always use sterile techniques when handling and wear personal protective equipment.
Research Disclaimer
This product is intended solely for in vitro scientific research and is not suitable for human consumption, diagnostic, or therapeutic purposes. Semaglutide should only be used by qualified researchers in controlled laboratory environments. Dutch Peptide Labs assumes no responsibility for misuse of this product. Users must comply with all relevant safety protocols and local regulations. This product has not been approved by the FDA, EMA, or other regulatory bodies for medical use.
